ADmit THERAPEUTICS - test for an early AD detection. Alzheimer's disease
test for an early AD detectionAlzheimer's disease
test for an early AD detectionAlzheimer's disease  

DETECTION IN CLINICAL PRACTICE

ADmit Therapeutics, S.L. is a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL), and focused on the development and commercialization of a novel Alzheimer's disease (AD) early detection technology.
Rigurosity RigurosityOur clinical studies are rigurously analyzed Efficiency EfficiencyWe optimize our own resources Agility AgilityWe adopt agile decissions

TEAMWORK AND INNOVATION

Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau.
Our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.

News

DemoDay at La Salle Technova
We present our project in the DemoDay in La Salle Technova, where Ship2B impulse with big corporates. https://twitter.com...

read more

OUR TEAM

Marta Barrachina Marta BarrachinaCEO
CO-FOUNDER
       
Ramón Reñé Ramón ReñéMEDICAL ADVISORY BOARD
CO-FOUNDER
  
MD, PhD in Medicine and Surgery
(Autonomous University of Barcelona)
Jordi Gascón Jordi GascónMedical Advisory Board
CO-FOUNDER
  
MD in Medicine and Surgery
(Autonomous University of Barcelona)
This website uses cookies, both our own and third party cookies, to improve your online experience and collect statistical information on browsing patterns.
By continuing to use this website, you consent cookies being installed on your browser. More information on our Cookies Policy